Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study

Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study

IntroductionPatients with relapsed or refractory multiple myeloma (RRMM) are likely to be living with persistent symptoms, especially bone pain and fatigue, and experiencing restrictions in their physical and social functioning, which reduce health-related quality of life.MethodsThis qualitative int...

Full description

Bibliographic Details
Main Authors: Anna Cardellino, Julia R. Correll, Mona Martin, Boris Gorsh, Sandhya Sapra, Rakesh Popat
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
belantamab mafodotin
multiple myeloma
embedded qualitative interviews
disease impact
B-Cell maturation antigen
immunomodulatory drug
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1274659/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1274659/full

Similar Items